Page 3 - Coronavirus Vaccine

AstraZeneca's anti-Covid drug cuts disease risk in vulnerable patients

The long-acting antibody therapy called sipavibart showed a "statistically significant reduction" in symptomatic Covid-19 cases among immunocompromised patients

After Covishield, new study 'finds' side effects in Covaxin recipients

In observational study on Bharat Biotech's Covaxin recipients, about one-third of participants reported adverse events

Rare blood clots from J&J and AstraZeneca Covid shots linked to genetics

Out of more than 18 million people who received the single-dose J&J vaccine, 60 cases of the clotting disorder were reported and nine people died, according to the Yale School of Medicine

Novavax signs Covid-19 license deal with Sanofi, secures business viability

Novavax said it would co-commercialize its Covid-19 vaccine with French drugmaker Sanofi and develop new Covid-19-influenza combination vaccines using Novavax's Matrix-M adjuvant

Covishield side effects: Doctors' group urges to review all Covid vaccines

In the wake of pharmaceutical giant AstraZeneca admitting in a UK court that its Covid vaccine can cause blood clots in rare cases, a group of doctors on Thursday expressed deep concern over the safety of the Covishield vaccine manufactured by the Serum Institute of India. At a press conference, the doctors, under the banner of the Awaken India Movement (AIM), urged the government to review the science behind all Covid vaccines and audit their commercialisation as well as implementation of active surveillance and monitoring mechanism to ensure vaccine adverse events are identified as early as possible. "The government has wholly ignored the rising number of cases of tragic deaths post-Covid vaccination all the while and continues to promote Covid vaccines as 'safe and effective', without scientific investigation and invoking epidemiology," Dr Tarun Kothari, a radiologist and an activist, said at the press conference. The world is learning about a side effect of the Covid vaccine ...

AstraZeneca to withdraw Covid-19 vaccine Vaxzevria globally on weak demand

AstraZeneca will start the withdrawal of marketing authorisation for the vaccine in Europe

Not producing, distributing Covishield since December 2021: Serum Institute

AstraZeneca Covid vaccine row: As of April 30, 2024, over 1.7 billion doses of the Covishield vaccine has been administered in India

Serum Institute responds for first time on Covishield amid safety row

Serum Institute of India says it stopped manufacturing Covishield since December 2021

AstraZeneca withdraws its Covid-19 vaccine, cites 'surplus availability'

According to media reports, the Anglo-Swedish drugmaker has previously admitted in court documents that the vaccine causes side-effects such as blood clots and low blood platelet counts

FLiRT 2024: New group of Covid variants spreads in US; all you need to know

FLiRT, a group of new Covid variants in the Omicron JN.1 lineage, is spreading in the US. KP.2 and KP 1.1 are more infectious than earlier Omicron variants, which, however, have similar side effects

Plans afoot to organise Kolhapuri chappal trade but it's a slow start

Though the Kolhapuri chappal trade is robust, the industry remains largely unorganised and finds it challenging to meet demand

As Xi Jinping visits Europe, Ukraine, trade likely to be top priority

Ukraine, trade and investment are expected to dominate Chinese leader Xi Jinping's first trip to Europe in five years, as the Asian giant rebuilds its foreign relations after a prolonged absence during the Covid-19 pandemic. Xi will start the tour in Paris on Monday, meeting with French President Emmanuel Macron, who has been stressing the idea of European strategic autonomy from the U.S. On a visit to Beijing last year, Macron courted controversy by saying France would not necessarily always align with the US in foreign policy, an apparent reference to American support for the self-governing republic of Taiwan, which China claims as its own territory to be annexed by force if necessary. After leaving France, Xi will visit Hungary and Serbia, both seen as China-friendly and close to Russian President Vladimir Putin, rebuffing Western criticism of his full-scale invasion of Ukraine. Xi's European visits will be closely followed in Washington for signs of diminishing support for its k

India premier destination for global clinical trials, says Harvard scholar

India has emerged as a premier destination for conducting global clinical trials, an Indian bureaucrat who is also a Harvard scholar has said, asserting that the pharma industry must recognise the country's intrinsic value as a primary location rather than relegating it to a secondary backup role. Speaking at a recent Bio-Pharma summit in Boston, Dr Mrinalini Darswal, an Indian diplomat who is currently a PhD scholar at Harvard University, said that India "boasts a robust infrastructure, a cadre of seasoned investigators, and cost-effectiveness, collectively rendering it an appealing choice for such endeavours. The present aspirational India under the strong and transformative leadership of our Prime Minister Narendra Modi has emerged as a premier destination for conducting global clinical trials, having streamlined its regulatory framework and elevated its compliance standards to align with international good clinical practices, Darswal said. This starkly contrasts larger economies

PM Modi missing from Covid certificates after Covishield row: Here's why

Ministry of Health and Family Welfare informed that PM Modi's photo was removed from Covid certificates due to the Model Code of Conduct (MCC) in effect for the ongoing Lok Sabha polls

AstraZeneca admits Covishield has rare side effect: Is concern warranted?

AstraZeneca's acknowledgment that the vaccine may lead to thrombosis isn't a new revelation, but it underscores the need for transparent communication by the pharma companies, say experts

Covishield vaccine case: Plea filed in SC seeking probe on AstraZeneca

AstraZeneca, facing a lawsuit in UK for alleged vaccine-related deaths and injuries, has acknowledged that its vaccine can cause Thrombosis with Thrombocytopenia Syndrome (TTS)

Astrazeneca row: Only 7 in a million at risk of TTS, says ex-ICMR scientist

Former ICMR scientist Raman Gangakhedkar said the risk is highest after the initial dose, eventually decreasing with subsequent doses

Centre needs to work on war footing to deal Covishield side effects: AAP

Delhi Health Minister Saurabh Bharadwaj on Wednesday said there was need to deal with the "rare side effects" of Covishield vaccine on a war footing and alleged that the central government has done nothing so far in the matter. In a press conference, Bharadwaj said that the Centre should talk to the vaccine manufacturing company, doctors and scientists for devising a mechanism to help people detect "warning signs or symptoms" of any side effects of the vaccine. "This issue should not be politicised but the Centre has been sleeping and it has done nothing so far. This vaccine was banned in many European countries in 2021 when government in our country was administering and promoting it, " he said. Bharadwaj said there were already questions in the minds of the people if the vaccine was in any way linked to the "sudden rise in heart attack cases". There were numerous videos of people suddenly collapsing and dying during workouts and other such normal activities in different parts of

Parents to sue Serum Institute over daughter's alleged Covishield death

Father says that AstraZeneca's admission of vaccine's rare side effect is 'too late'

AstraZeneca responds to Covishield vaccine concerns: Here's what they said

Regulatory agencies around the world maintain that the risks from the vaccine outweigh the benefits